the india story

Patients are waiting, for the revolution

Home to one-sixth of humanity, India is the 4th largest global economy, and the
fastest growing amongst the G20. It is a rapidly developing nation with a large and rising cancer burden. A little more than 1 million new cases of cancer are
diagnosed every year in India (~ 8% of the world’s cancer patients are in India).

Despite a lower incidence of cancer, India suffers a higher mortality rate comparatively. Without access to advanced interventions, this number is estimated to rise to over 1.3 million by 2040.

Source: Globocan 2020

India: Not on the cell therapy map, yet

CAR-T cell trials and geographical distribution

Despite India’s pressing need for more effective therapies against cancer, there is still no access to commercial cell therapy solutions in India.

Immuneel has taken a lead to change this landscape with ‘IMAGINE’ – India’s first Phase 2 trial for CD19 CAR-T (IMN-003A) for B cell malignancies (Leukemia & Lymphoma) – with the goal of making CAR-T cell therapy commercially available to patients soon.

CAR-T cell trials and geographical distribution

Source: clinicaltrials.gov

India, a crucible for affordable cell and gene therapy

Despite the immensity of the challenge, India is best placed to catalyze this revolution on affordable cell and gene therapies. It has –

specialist healthcare professionals who are widely regarded as among the world’s best clinicians.
a reputation as a global destination for patients seeking quality, affordable care.
well developed oncology hospitals and a network of expert and experienced oncologists.
rich scientific and technical talent pool.

sophisticated, mature bio-pharmaceutical manufacturing companies that operate globally.
growing government endowments to build a biotechnology capability and eco-system.
supporting regulatory frameworks harmonized to global standards and guidelines.
a large, dynamic, well run market system that mandates cost consciousness and affordability as the key for accessibility.

Immuneel, bridging the gap

With access to technology and capital, the gap between promise and reality is set to close. We are bridging the gap between patients and technology bringing cell therapies to patients, at their hospitals.

Immuneel is an Indian company, built with a purpose: to bring cutting-edge immuno-oncology therapies, affordably and accessibly, to India.

From here to the horizon

Immuneel is investing in India, for India, during the early days of the era of cell and gene therapies.

The goal is an ever-broadening base for leading edge cell and gene-based therapies. With capital, technology and capability Immuneel is uniquely poised to bring about radical change in India’s healthcare paradigm through access to cell therapy solutions, dedicated infrastructure and affordable delivery.

the unique partnering opportunities with immuneel

Immuneel’s bold thrust to expand the treatment base for cell and gene therapies, by taking advantage of India’s high quality, lower cost talent and infrastructure.

1 First mover

It is leading as a first mover in India, with a rapid start of these therapies made in India. For India.

2 Hub and node

A central hub providing technology services, products, protocols, and training to partner hospitals at the nodes.

3 Regulatory

Immuneel is working with Indian regulators towards a new, positive regulatory framework for cell & gene therapies in India.

4 Oncology network

Immuneel leverages its oncology physician network and hospitals, especially with bone marrow transplant units.

5 Dedicated patient infrastructure

Unique location of Immuneel gives it better access to run multi-center clinical trials and better patient care.

6 Future off the shelf products

Allogeneic products, which do not need the patient’s cell and can be available as ready to use in hospitals.

The goal

A success in India—against the challenges of delivering a new medical technology with relative affordability—is a remarkable beacon for the world. And a potential springboard for cutting-edge immunotherapy.